Childrens Cancer Research Institute St Anna Childrens Hospital Vienna Austria

Department of Neurology Sheba Medical Center Tel Hashomer Israel

Department of Pediatric Oncology Hematology and Clinical Immunology Heinrich Heine University Düsseldorf Medical Faculty Düsseldorf Germany

Department of Pediatrics Pediatric Hematology and Oncology University Hospital Carl Gustav Carus Technische Universität Dresden Fetscherstrasse 74 01307 Dresden Germany

Department of Systems Biology Beckman Research Institute and City of Hope Comprehensive Cancer Center Pasadena CA USA

Division of Pediatric Hematology and Oncology Schneider Children's Medical Center and Tel Aviv University Tel Aviv Israel

Fujian Institute of Hematology Fujian Provincial Key Laboratory of Hematology Fujian Medical University Union Hospital 350001 Fuzhou Fujian China

Institute of Pharmaceutical and Medicinal Chemistry Heinrich Heine Universität Düsseldorf 40225 Düsseldorf Germany

John von Neumann Institute for Computing Forschungszentrum Jülich GmbH 52425 Jülich Germany

National Center for Tumor Diseases Dresden Germany

Pediatric Hematology Oncology Childhood Leukemia Investigation Prague Prague Czech Republic

Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

The Joseph Sagol Neuroscience Center Sheba Medical Center Tel Hashomer Israel

See more in PubMed

Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373:2336–46. doi: 10.1056/NEJMoa1508054. PubMed DOI PMC

Mullighan CG. Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest. 2012;122:3407–15. doi: 10.1172/JCI61203. PubMed DOI PMC

Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45:242–52. doi: 10.1038/ng.2532. PubMed DOI PMC

Churchman ML, Qian M, Te Kronnie G, Zhang R, Yang W, Zhang H, et al. Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia. Cancer Cell. 2018. PubMed PMC

Brozou T, Taeubner J, Velleuer E, Dugas M, Wieczorek D, Borkhardt A, et al. Genetic predisposition in children with cancer—affected families’ acceptance of Trio-WES. Eur J Pediatr. 2018;177:53–60. doi: 10.1007/s00431-017-2997-6. PubMed DOI PMC

Kuhlen M, Borkhardt A. Trio sequencing in pediatric cancer and clinical implications. EMBO Mol Med. 2018. PubMed PMC

Stanulla M, Dagdan E, Zaliova M, Moricke A, Palmi C, Cazzaniga G, et al. IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric b-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2018;36:1240–9. doi: 10.1200/JCO.2017.74.3617. PubMed DOI

Nan J, Hu H, Sun Y, Zhu L, Wang Y, Zhong Z, et al. TNFR2 stimulation promotes mitochondrial fusion via Stat3- and NF-kB-dependent activation of OPA1 expression. Circ Res. 2017;121:392–410. doi: 10.1161/CIRCRESAHA.117.311143. PubMed DOI PMC

Shochat C, Tal N, Bandapalli OR, Palmi C, Ganmore I, te Kronnie G, et al. Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med. 2011;208:901–8. doi: 10.1084/jem.20110580. PubMed DOI PMC

Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, et al. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med. 2016;22:379–87. doi: 10.1038/nm.4062. PubMed DOI PMC

James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8. doi: 10.1038/nature03546. PubMed DOI

Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371:1005–15. doi: 10.1056/NEJMoa1403088. PubMed DOI PMC

Schwartzman Omer, Savino Angela Maria, Gombert Michael, Palmi Chiara, Cario Gunnar, Schrappe Martin, Eckert Cornelia, von Stackelberg Arend, Huang Jin-Yan, Hameiri-Grossman Michal, Avigad Smadar, te Kronnie Geertruy, Geron Ifat, Birger Yehudit, Rein Avigail, Zarfati Giulia, Fischer Ute, Mukamel Zohar, Stanulla Martin, Biondi Andrea, Cazzaniga Giovanni, Vetere Amedeo, Wagner Bridget K., Chen Zhu, Chen Sai-Juan, Tanay Amos, Borkhardt Arndt, Izraeli Shai. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. Proceedings of the National Academy of Sciences. 2017;114(20):E4030–E4039. doi: 10.1073/pnas.1702489114. PubMed DOI PMC

Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down’s syndrome. Lancet. 2008;372:1484–92. doi: 10.1016/S0140-6736(08)61341-0. PubMed DOI

Izraeli S. The acute lymphoblastic leukemia of Down syndrome—genetics and pathogenesis. Eur J Med Genet. 2016;59:158–61. doi: 10.1016/j.ejmg.2015.11.010. PubMed DOI